Tenax Therapeutics, Inc.TENXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank71
5Y CAGR+38.0%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+38.0%/yr
Long-term compound
Percentile
P71
Within normal range
vs 5Y Ago
5x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 157.08% |
| 2024 | 293.59% |
| 2023 | -39.95% |
| 2022 | -78.62% |
| 2021 | 451.39% |
| 2020 | 31.39% |
| 2019 | 180.09% |
| 2018 | -64.87% |
| 2017 | -89.96% |
| 2016 | 427.59% |